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Background: To describe the possible role of oxaliplatin in worsening pre-existing
interstitial lung disease.
Methods: After we encountered a patient with an interstitial lung disease who
experienced a fatal progression of his pulmonary disease associated with oxaliplatin
therapy, a computer-aided search was conducted to identify other similar patients.
Twenty-six patients with various lung diseases who had received oxaliplatin therapy at
Mayo Clinic in Rochester, MN from January 2000 to December 2006 were identified. Three
of these patients had radiologic evidence of interstitial lung disease before undergoing
oxaliplatin therapy. We examined the medical records and imaging studies of these three
patients to further define their clinical presentation, radiological and functional
characteristics, and clinical outcome.
Results: All three patients experienced symptomatic and radiologic worsening of their
interstitial lung disease following oxaliplatin administration. One of these patients died
from refractory respiratory failure; the remaining two patients stabilized after the
discontinuation of oxaliplatin therapy and have since shown modest improvement in
pulmonary symptoms and lung function. There were no other potential causes identified
for the unexpected progression of their lung disease other than the temporal relationship
to oxaliplatin therapy.
Conclusions: Treatment with oxaliplatin, in the setting of a pre-existing interstitial lung
disease, may be associated with respiratory deterioration. It is unknown whether this isElsevier Ltd. All rights reserved.
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B.E. Wilcox et al.274mediated by acceleration of the underlying parenchymal disease or by a superimposed
acute lung injury caused by oxaliplatin.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Oxaliplatin is a platinum derivative chemotherapeutic agent
approved by the Food and Drug Administration in 2002 for
the treatment of metastatic colorectal cancer (CRC). Since
this approval, an oxaliplatin-based regimen that includes
fluorouracil and leucovorin (FOLFOX) has become first-line
therapy for treatment of metastatic CRC. Randomized
controlled trials have shown significantly greater response
rates and disease-free survival using FOLFOX when com-
pared with fluorouracil and leucovorin alone, and superior
results to a regimen of irinotecan combined with fluorouracil
and leucovorin.1–4 The initial studies examining the toxi-
cities of oxaliplatin showed hematologic, gastrointestinal
and neurologic complications but no pulmonary complica-
tions.5 More recently, there have been reports of patients
developing interstitial lung diseases (ILD),6–8 acute lung
injury,9 eosinophilic lung disease,10 hypersensitivity reac-
tions and wheezing associated with oxaliplatin infusion.5,11
We recently encountered a patient who suffered fatal
progression of ILD associated with oxaliplatin therapy. We
subsequently conducted a computer-aided search to identify
other patients with ILD seen at Mayo Clinic in Rochester, MN
from January 2000 to December 2006 and received
oxaliplatin therapy. This search yielded 26 patients with
various lung diseases who were treated with oxaliplatin
therapy for their CRC. Only three of these 26 patients had
radiologic evidence of ILD prior to administration of
oxaliplatin therapy and all developed symptomatic and
radiologic worsening of their ILD after initiation of FOLFOX
regimen in the treatment of metastatic CRC.Case 1
A 71-year-old man with a history of mild bibasilar pulmonary
infiltrates consisting of subpleural, reticular opacities on high-
resolution computed tomographic (HRCT) scan, was diagnosed
with CRC in 2005. Pulmonary infiltrates were first noted in
1999 when the patient was asymptomatic. Pulmonary function
tests (PFT) revealed only minimal abnormalities consisting
of a mildly reduced forced vital capacity (FVC) of 3.47 L
(74% predicted) and forced expiratory volume in 1 s (FEV1) of
2.77 L (77% predicted) with normal total lung capacity (TLC)
5.70 L (83% predicted) and diffusing capacity (DLCO)
23.1mlCO/mmHg/min (84% predicted). There was no history
of relevant exposures and evaluation for potential causes of
ILD, including serologic testing for connective tissue disease
(CTD), was unrevealing with negative rheumatoid factor, anti-
cyclic citrullinated peptide antibody, antinuclear antibody,
and antibody to extractable nuclear antigen. There was no
evidence of radiologic or symptomatic progression on re-
peated evaluations between 1999 and 2005 and no lung biopsy
was performed.
The patient underwent resection of the primary CRC
lesion and subsequently six cycles of FOLFOX therapybeginning in 2005. His chemotherapy regimen included
intravenous oxaliplatin 180mg, leucovorin 860mg and
fluorouracil 5130mg per cycle. No complications were noted
through the first five cycles of FOLFOX therapy; however, his
sixth cycle of oxaliplatin infusion was interrupted because of
acute dyspnea and cough. Chest radiography revealed new
parenchymal infiltrates. These abnormalities were thought
to represent a hypersensitivity reaction to oxaliplatin and
were treated with oral methylprednisolone starting at 24mg
orally daily and tapering by 4mg per day over 5 days. His
symptoms and radiographic infiltrates improved. Three
weeks following this episode, he again noted increasing
exertional dyspnea along with fever (T ¼ 39.0 1C). He was
found to be profoundly hypoxemic (oxygen saturation
70–75% on room air at rest) and was hospitalized for further
management.
On admission, he was tachypneic with respiratory rates in
the high 30’s and required supplemental oxygen via a
nonrebreather mask with a fractional concentration of
inspired oxygen (FiO2) of 1.0. Despite the high FiO2, his
arterial blood gas study showed a pH of 7.43, PCo2 of 27, PO2
of 58 and oxygen saturation of 88%. Other laboratory data
included hemoglobin 12.8mg/dL, leukocytes 13.9 109 L1
and a normal platelet count. An electrocardiogram demon-
strated normal sinus rhythm without signs of ischemia. An
echocardiogram showed normal left ventricular ejection
fraction of 55%, mild (grade 1/4) diastolic dysfunction,
and a mildly elevated estimated right ventricular systolic
pressure of 44mmHg. Computed tomographic angiography
(CTA) was negative for pulmonary embolism but showed
extensive new areas of ground-glass opacities bilaterally
(Figure 1).
Multiple blood, sputum, and urine cultures failed to
demonstrate any infection. Bronchoscopy with bronchoal-
veolar lavage also did not identify any infectious agent.
Following bronchoscopy, his oxygenation worsened further
and he required endotracheal intubation with mechanical
ventilatory support. He was empirically treated with
vancomycin, levofloxacin and meropenem as well as high-
dose corticosteroids (intravenous methyprednisolone 250mg
per day for 14 days), but continued to worsen. Another chest
CT scan was performed and demonstrated an increased
amount of fibrotic-appearing infiltrates as well as the
ground-glass opacities. Maintaining adequate oxygenation
with mechanical ventilation became increasingly difficult
for which inhaled nitric oxide, high-frequency oscillator
ventilation as well as prone positioning were instituted with
only limited and transient benefit. He ultimately succumbed
to refractory respiratory failure after 30 days of mechanical
ventilation. An autopsy request was declined.Case 2
The second patient is a 77-year-old woman who was
diagnosed with CRC in February 2006 at an outside
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Figure 1 Patient 1: (A) HRCT 1 month before FOLFOX therapy demonstrating mild subpleural bibasilar infiltrates. (B) HRCT after
FOLFOX therapy with extensive fibrotic infiltrates and new ground-glass opacities.
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with a clinical stage of T3N1M0. Following her surgery and
staging, she underwent 12 cycles of FOLFOX therapy
(intravenous oxaliplatin 110mg, leucovorin 530mg and
fluorouracil 3150mg) between March and August 2006.
Within 1 month of the completion of her chemotherapy
she began to notice a dry, nonproductive cough and dyspnea
on exertion and was referred to our Pulmonary Clinic for
additional evaluation in November 2006. She had no
previous diagnosis of lung disease.
Imaging with an HRCT scan of the chest showed features
of a nonspecific interstitial pneumonia consisting of mild
subpleural, bibasilar pulmonary infiltrates of reticular
character as well as ground-glass opacities (Figure 2).12
Search for previous chest imaging studies yielded a CTof theabdomen, performed at the time of her CRC diagnosis 9
months before, that displayed ground-glass opacities in the
right lung base. PFT revealed normal lung volumes with a
decreased DLCO of 9.3ml CO/mmHg/min (54% of predicted)
and oxygen desaturation from 97% at rest to 87% with
minimal exercise on room air. There had been no previous
PFT.
She was a never-smoker and had not been exposed to any
other fibrogenic medications or environmental agents.
There was no evidence for an underlying systemic disorder
such as a CTD. She declined further evaluation including
bronchoscopic or surgical lung biopsy. Over the subsequent 6
months following her last infusion of oxaliplatin, she
exhibited gradual improvement in her cough and dyspnea.
Repeat PFT showed stable expiratory flows and volumes
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Figure 2 Patient 2: (A) CT 1 month before FOLFOX therapy with ground-glass opacities. (B) HRCT after FOLFOX therapy with
subpleural, bibasilar pulmonary infiltrates and progression of ground-glass opacities.
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mmHg/min, and stable findings on HRCT, without specific
therapy.Case 3
The third patient is a 69-year-old man without any known
lung disease who was diagnosed with CRC in December 2005
at an outside institution. He underwent a right hemicolect-
omy with clinical staging of T3N2M0. Following surgery,
chemotherapy with a FOLFOX regimen (unknown doses) was
administered for six cycles from February 2006 to August
2006. He had no complications with his therapy until his lastcycle when he noted increasing shortness of breath and
fatigue. At that time, his oxygen saturation was 75% on room
air. He noted no fever, chills or cough.
He was admitted to an outside hospital for additional
evaluation of his hypoxemia. A CTA was negative for
pulmonary embolism but showed fibrotic-appearing pulmon-
ary infiltrates bilaterally with honeycombing and traction
bronchiectasis. He was treated with intravenous antibiotics
(levofloxacin and azithromycin) without clinical or radio-
graphic improvement. A bronchoscopy with transbronchial
biopsies was performed and revealed a small focus of
organizing pneumonia and reactive type II pneumocytes.
Following the biopsy he was started on prednisone 40mg
daily for a presumed diagnosis of cryptogenic organizing
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the time of his discharge from the hospital and continued
to take 40mg of prednisone daily for 1 month without
improvement in symptoms or radiographic appearance. In
addition, his oxygen requirements gradually increased
during this interval.
He was referred to our Pulmonary Clinic for additional
evaluation in November 2006. At that visit he was requiring
4 L/min of supplemental oxygen via nasal cannula to
maintain oxygen saturations above 90% and was tachypneic
with minimal exertion. There was no history of relevant
exposures, other than FOLFOX therapy, or evidence of
underlying disorders. Further review of the patient’s
previous imaging studies revealed subpleural, bibasilar
infiltrates to have been present on a CT scan of the chest
performed a month prior to starting chemotherapy. HisFigure 3 Patient 3: (A) CT 1 month before FOLFOX therapy with m
glass opacities. (B) HRCT after FOLFOX therapy with subpleural h
radiologic appearance of usual interstitial pneumonia.13current HRCT chest showed significant worsening of the
interstitial process with subpleural honeycombing and
traction bronchiectasis predominately in the lower lungs
consistent with an usual interstitial pneumonia pattern
(Figure 3).13 PFT demonstrated a restrictive defect with
a low TLC of 5.01 L (70% predicted), FVC 3.18 L (65%
predicted), FEV1 2.37 L (64% predicted) and a severely
reduced DLCO 8.5ml CO/mmHg/min (31% predicted); no
previous studies were available. Echocardiogram was nor-
mal. The patient declined a lung biopsy for further
diagnostic evaluation. Empiric therapy with N-acetylcys-
teine 600mg orally three times daily was initiated.
The patient had a dramatic improvement in his symptoms
when he was seen in follow-up 5 months (8 months after his
last infusion of oxaliplatin) after his initial clinical evalua-
tion. The patient had a decrease in his supplemental oxygenild subpleural, predominantly right-sided infiltrates and ground-
oneycombing and traction bronchiectasis consistent with the
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breath. In addition, repeat PFT displayed improvement in
his lung function with a TLC of 6.58 L (91% of predicted), FVC
of 4.18 L (83% of predicted), FEV1 of 2.73 (72% of predicted)
and DLCO of 10.3ml of CO/mmHg/min (38% of predicted).Discussion
The FOLFOX regimen has provided an increase in disease-
free survival as well as an overall mortality benefit for
patients with metastatic CRC.1–4 The initial safety studies
evaluating FOLFOX therapy did not find any significant
pulmonary complications with the exception of dyspnea
related to infusion and hypersensitivity reactions.5 In
addition, the non-oxaliplatin containing chemotherapy
previously used for CRC, leucovorin and fluorouracil, has
not been noted to have significant pulmonary toxicity in
safety trials or during subsequent extensive clinical use.
Although the available data suggests that oxaliplatin is not
associated with significant pulmonary toxicity, our observa-
tions suggest there may be a subgroup of patients,
specifically those with pre-existing ILD, who are at increased
risk of major pulmonary toxicity from oxaliplatin.
There has been no direct evidence implicating oxaliplatin
with a parenchymal lung reaction and no potential mechan-
isms of injury has been identified for lung injury related to
this chemotherapeutic agent. However, there are data that
suggest oxaliplatin may predispose to glutathione depletion
and this may be part of the pathogenesis of oxaliplatin
related liver injury leading to hepatic sinusoidal obstruction
associated with endothelial injury and perivenular fibrosis.14
Glutathione is a major small molecular antioxidant of human
lung that may be protective against oxidant-mediated lung
damage; depletion secondary to oxaliplatin may provide the
key to explaining the progression of ILD seen in our
patients.15 It is premature to extrapolate that administra-
tion of anti-oxidant agents may be potentially useful but
Patient 3 seemed to show an unexpected benefit with
N-acetylcysteine which may potentially replete glutathione.
All three patients described here had CT findings
consistent with ILD12 before initiation of FOLFOX therapy
with minimal or no respiratory symptoms. All of them
experienced symptomatic and radiologic worsening of their
lung disease after initiation of FOLFOX therapy. In two of our
patients, the radiologic abnormalities had not been thought
to be of significance at the time of the imaging study and
were identified only in retrospective review. These patients
had no explanation for exacerbation of their lung disease
other than the temporal relationship to their chemotherapy.
In addition, limited follow-up with two patients has shown
an interval improvement in their subjective symptoms and
objective data. This improvement is atypical of the natural
history of untreated ILD and supports that an exacerbating
event or new lung injury occurred to explain the worsening
of their lung disease. Of the remaining 23 patients with lung
disease who received oxaliplatin, as identified in our search
of patient records, none had an interstitial process and none
was identified as having a worsening in respiratory status.
It is unclear whether this worsening of pre-existing ILD is
exclusively due to oxaliplatin or whether it represents a
platinum-derivative drug class effect. A review of theliterature revealed two studies16,17 examining pulmonary
toxicity induced by combination chemotherapy that in-
cluded carboplatin. Both studies, one involving combination
chemotherapy with paclitaxel and the other with gemcita-
bine, concluded that therapy induced reversible isolated
decreases in DLCO without clinical or radiographic evidence
of pulmonary toxicity, but that this was not attributable to
carboplatin. Interestingly, one of the study patients treated
with gemcitabine and carboplatin was noted to have a low
DLCO at baseline.16 The patient developed increasing
dyspnea and fibrotic changes on HRCT shortly following his
chemotherapy, which resolved after treatment with corti-
costeroids. There is no mention of pre-treatment imaging
and no way to definitively know if the patient had underlying
ILD or if the toxicity was induced by gemcitabine or
carboplatin.
The current recommendations for pre-chemotherapy
evaluation of CRC do not include any imaging or functional
assessment of the lungs. Observations regarding our three
patients raise concern regarding potential pulmonary
toxicity associated with the use of oxaliplatin therapy in
patients with pre-existing ILD. Additional studies are needed
to explore this association which, if confirmed, may provide
grounds to modify current clinical practice in this regard.
For example, screening for pre-existing ILD with pulmonary
function testing and/or HRCT of the chest may need to be
considered prior to institution of oxaliplatin or platinum
derivative therapy.
In conclusion, we have described three patients with pre-
existing mild ILD who experienced worsening of their lung
disease associated with oxaliplatin therapy and included a
death from respiratory failure. These observations warrant
further investigation of possible association that may lead to
acute respiratory failure.
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